Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case -142% Improvement Relative Risk Case -6% c19hcq.org Juneja et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 2,200 patients in India (April - September 2020) Higher severe cases with HCQ (not stat. sig., p=0.59) Juneja et al., J. Basic and Clinical Physiology .., doi:10.1515/jbcpp-2021-0221 Favors HCQ Favors control
Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India
Juneja et al., Journal of Basic and Clinical Physiology and Pharmacology, doi:10.1515/jbcpp-2021-0221
Juneja et al., Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers:.., Journal of Basic and Clinical Physiology and Pharmacology, doi:10.1515/jbcpp-2021-0221
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 2,200 healthcare workers in India, 996 taking HCQ prophylaxis, showing no significant differences. There were large differences in the occupation of participants and therefore exposure, and the authors make no adjustments. This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of severe case, 141.8% higher, RR 2.42, p = 0.59, treatment 2 of 996 (0.2%), control 1 of 1,204 (0.1%).
risk of case, 6.4% higher, RR 1.06, p = 0.67, treatment 103 of 996 (10.3%), control 117 of 1,204 (9.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Juneja et al., 7 Jan 2022, retrospective, India, peer-reviewed, 9 authors, study period 2 April, 2020 - 3 September, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: J Basic Clin Physiol Pharmacol 2022; aop Shivani Juneja, Proteesh Rana*, Parvinder Chawala, Rekha Katoch, Kulvir Singh, Shobha Rana, Tamanna Mittal, Bhavnish Kaur and Simaranjot Kaur Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India https://doi.org/10.1515/jbcpp-2021-0221 Received August 15, 2021; accepted December 20, 2021; published online January 7, 2022 Abstract Objectives: The use of Hydroxychloroquine (HCQ) prophylaxis has been recommended by the National task force constituted by the Indian Council of Medical Research (ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers (HCWs). However, this recommendation was based essentially on the preclinical data and limited clinical experience. The aim of this study was to evaluate the efficacy and safety of HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs. Methods: A cross-sectional study was conducted among HCWs of a tertiary care hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were followed up to 8 weeks for conversion to COVID-19 positive status and any adverse drug reaction (ADR). Results: About 10.3% of the study participants were tested positive for COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis (9.7%). Conclusions: HCQ was well tolerated at a weekly dose of 400 mg for 8 weeks but provided no additional benefit in prevention of COVID-19 among HCWs. Keywords: COVID-19; Hydroxycholoroquine; prophylaxis. *Corresponding author: Proteesh Rana, Assistant Professor, Department of Pharmacology, University College of Medical Sciences, Delhi, India, E-mail: proteesh@gmail.com Shivani Juneja, Department of Clinical Pharmacology, Fortis Hospital Mohali, Mohali, India Parvinder Chawala, Rekha Katoch, Kulvir Singh, Shobha Rana, Tamanna Mittal, Bhavnish Kaur and Simaranjot Kaur, Fortis Hospital Mohali, Mohali, Punjab, India
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit